6 research outputs found
Hollow Fiber Membrane Modification with Functional Zwitterionic Macromolecules for Improved Thromboresistance in Artificial Lungs
Respiratory
assist devices seek optimized performance in terms
of gas transfer efficiency and thromboresistance to minimize device
size and reduce complications associated with inadequate blood biocompatibility.
The exchange of gas with blood occurs at the surface of the hollow
fiber membranes (HFMs) used in these devices. In this study, three
zwitterionic macromolecules were attached to HFM surfaces to putatively
improve thromboresistance: (1) carboxyl-functionalized zwitterionic
phosphorylcholine (PC) and (2) sulfobetaine (SB) macromolecules (mPC
or mSB-COOH) prepared by a simple thiol-ene radical polymerization
and (3) a low-molecular weight sulfobetaine (SB)-<i>co</i>-methacrylic acid (MA) block copolymer (SBMAb-COOH) prepared by reversible
addition–fragmentation chain transfer (RAFT) polymerization.
Each macromolecule type was covalently immobilized on an aminated
commercial HFM (Celg-A) by a condensation reaction, and HFM surface
composition changes were analyzed by X-ray photoelectron spectroscopy.
Thrombotic deposition on the HFMs was investigated after contact with
ovine blood in vitro. The removal of CO<sub>2</sub> by the HFMs was
also evaluated using a model respiratory assistance device. The HFMs
conjugated with zwitterionic macromolecules (Celg-mPC, Celg-mSB, and
Celg-SBMAb) showed expected increases in phosphorus or sulfur surface
content. Celg-mPC and Celg-SBMAb experienced rates of platelet deposition
significantly lower than those of unmodified (Celg-A, >95% reduction)
and heparin-coated (>88% reduction) control HFMs. Smaller reductions
were seen with Celg-mSB. The CO<sub>2</sub> removal rate for Celg-SBMAb
HFMs remained comparable to that of Celg-A. In contrast, the rate
of removal of CO<sub>2</sub> for heparin-coated HFMs was significantly
reduced. The results demonstrate a promising approach to modifying
HFMs using zwitterionic macromolecules for artificial lung devices
with improved thromboresistance without degradation of gas transfer